Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Methods of modulating cytokine activity; related reagents
US9970944B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9970944-B2 |
| Application number | US-201414171629-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 3, 2014 |
| Priority date | Feb 17, 2004 |
| Publication date | May 15, 2018 |
| Grant date | May 15, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating an immune disorder of asthma or allergy in a subject, comprising administering a therapeutically effective amount of an antibody or antigen binding fragment that specifically binds to IL-33 to the subject in need thereof. 2. The method of claim 1 , wherein the immune disorder comprises a TH2-type response. 3. The method of claim 2 , wherein the TH2-type response comprises an early event in a TH2-type response. 4. The method of claim 1 , wherein the antibody or antigen binding fragment is: a) a polyclonal antibody; b) a monoclonal antibody; c) a humanized antibody, or a fragment thereof; or d) a Fab, Fv, or F(ab′) 2 fragment. 5. The method of claim 1 , wherein the immune disorder is asthma. 6. The method of claim 1 , wherein the immune disorder is allergy. 7. The method of claim 5 , wherein the asthma comprises a TH2-type response. 8. The method of claim 6 , wherein the allergy comprises a TH2-type response.
Assignees
Inventors
Classifications
Immunomodulators · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Drugs for immunological or allergic disorders · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9970944B2 cover?
- Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.
- Who is the assignee on this patent?
- Merck Sharp & Dohme
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).